- Home
- NRIX vs WLKP Comparison
NRIX vs WLKP Comparison
Compare NRIX & WLKP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRIX
- WLKP
- Stock Information
- Founded
- NRIX 2009
- WLKP 2014
- Country
- NRIX United States
- WLKP United States
- Employees
- NRIX N/A
- WLKP N/A
- Industry
- NRIX Biotechnology: Pharmaceutical Preparations
- WLKP Major Chemicals
- Sector
- NRIX Health Care
- WLKP Industrials
- Exchange
- NRIX Nasdaq
- WLKP Nasdaq
- Market Cap
- NRIX 908.0M
- WLKP 833.7M
- IPO Year
- NRIX 2020
- WLKP 2014
- Fundamental
- Price
- NRIX $11.64
- WLKP $22.16
- Analyst Decision
- NRIX Strong Buy
- WLKP
- Analyst Count
- NRIX 16
- WLKP 0
- Target Price
- NRIX $30.44
- WLKP N/A
- AVG Volume (30 Days)
- NRIX 857.7K
- WLKP 33.5K
- Earning Date
- NRIX 07-10-2025
- WLKP 08-05-2025
- Dividend Yield
- NRIX N/A
- WLKP 8.53%
- EPS Growth
- NRIX N/A
- WLKP N/A
- EPS
- NRIX N/A
- WLKP 1.49
- Revenue
- NRIX $56,417,000.00
- WLKP $1,088,852,000.00
- Revenue This Year
- NRIX $16.69
- WLKP $8.90
- Revenue Next Year
- NRIX N/A
- WLKP $6.87
- P/E Ratio
- NRIX N/A
- WLKP $14.84
- Revenue Growth
- NRIX N/A
- WLKP N/A
- 52 Week Low
- NRIX $8.18
- WLKP $21.19
- 52 Week High
- NRIX $29.56
- WLKP $25.04
- Technical
- Relative Strength Index (RSI)
- NRIX 54.44
- WLKP 51.80
- Support Level
- NRIX $11.17
- WLKP $21.82
- Resistance Level
- NRIX $11.99
- WLKP $22.36
- Average True Range (ATR)
- NRIX 0.58
- WLKP 0.27
- MACD
- NRIX -0.07
- WLKP 0.03
- Stochastic Oscillator
- NRIX 37.50
- WLKP 80.16
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
About WLKP Westlake Chemical Partners LP Common Units representing limited partner interests
Westlake Chemical Partners LP is a part of the chemical industry in the United States. Its operations are conducted through OpCo, it acquires and develops ethylene production facilities, which convert ethane into ethylene. OpCo sells ethylene and its co-products such as propylene, crude butadiene, pyrolysis gasoline, and hydrogen to Westlake and other customers located in the United States. Its assets include three ethylene production facilities in Calvert City, Kentucky, and Lake Charles, Louisiana.